Is Trident Lifeline Ltd (543616) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Trident Lifeline Ltd is a average quality company .

Is Trident Lifeline Ltd (543616) undervalued or overvalued?

The key valuation ratios of Trident Lifeline Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Trident Lifeline Ltd (543616) share price return in the past 10 years?

Data is not available for this company

Is Trident Lifeline Ltd (543616) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Trident Lifeline Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Trident Lifeline Ltd (543616)?

Company share prices are keep on changing according to the market conditions. The current trading price of Trident Lifeline Ltd (543616) on 17-Apr-2026 16:59:59 at 16:59 is 249.65.

What is the P/E ratio of Trident Lifeline?

The latest standalone P/E ratio of Trident Lifeline as of 17-Apr-2026 is 22.83.

What is the P/B ratio of Trident Lifeline Ltd (543616)?

The latest standalone P/B ratio of Trident Lifeline Ltd (543616) as of 17-Apr-2026 is 3.32.

What is the 52-week high and low of Trident Lifeline Ltd (543616)?

The 52-week high of Trident Lifeline Ltd (543616) is Rs. 328.00 and the 52-week low is Rs. 229.95.

Trident Lifeline Ltd (543616) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Trident Lifeline Ltd (543616)
Brand: Trident Lifeline

Trident Lifeline Ltd (543616) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Trident Lifeline Ltd (543616)

BSE: 543616 NSE:

Key Metrics

Market Cap

₹298 Cr.

P/E Ratio

22.83

Price to Book (P/B)

3.32

Price to Sales (P/S)

4.39

EV/EBITDA

15.20

Return on Capital Employed (ROCE)

27.66%

Current Price

₹249.7

Return on Equity (ROE)

22.05%

Return on Assets (ROA)

15.07%

Operating Profit Margin

26.1%

Net Profit Margin

19.25%

Gross Profit Margin

28.7%

Book Value per Share

₹75.2

Sales Growth (YoY)

51.85%

Sales Growth (3 Years)

46.04%

Operating Profit Growth (1 Year)

99.21%

Operating Profit Growth (3 Years)

86.82%

Net Profit Growth (1 Year)

85.37%

52-Week Low / High

₹230 / 328

Net Profit Growth (3 Years)

48.97%

Dividend Yield

0.00%

Promoter Holding

64.11%

Pledged shares (%)
of Promoter's holding (%)

6.77%

Check Before You Invest

Q.1 Revenue growth of Trident Lifeline Ltd?

Trident Lifeline Ltd revenue growth is 51.9% for FY-2025 , which is below its 5 year CAGR of 68.9% , indicating slower growth.

Q.1 Promoter shareholding and pledge status of Trident Lifeline Ltd?

Promoters hold 64.11% of the Trident Lifeline Ltd, with 6.77% of their stake pledged, indicating low pledge risk.

Q.1 Revenue growth of Trident Lifeline Ltd vs industry peers?

Trident Lifeline Ltd revenue CAGR is 68.92% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Trident Lifeline Ltd belong to?

Trident Lifeline Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Trident Lifeline Ltd over the last decade?

Over the last 3 year(s), the stock has delivered a CAGR of 17.73% based on the current price.

DeciZen - make an informed investing decision on Trident Lifeline

Based on:

Data

Overall Rating ⓘ
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

3. Price Trend

Trident Lifeline stock performance

Key Ratios

Is Trident Lifeline Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-9.1%	33.7%	55.1%	25.1%	19.1%	27.7%	-
Value Creation Index ⓘ	NA	1.4	2.9	0.8	0.4	1.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	4.9	9.6	21.8	31.7	44.7	67.8	68
Sales YoY Gr.	-	95.1%	126.3%	45.6%	40.9%	51.9%	-
Adj EPS ⓘ	-2.6	1.2	4.9	5.1	6	11.1	10.9
YoY Gr.	-	NA	314.5%	5.2%	18.2%	84.6%	-
BVPS (₹) ⓘ	-9.7	-0.9	6	39.7	45.8	57.1	75.2
Adj Net Profit ⓘ	-0.8	0.6	3.9	5.9	6.9	12.8	13
Cash Flow from Ops. ⓘ	-0.6	1.5	-0.2	-16.6	0.9	-3.5	-
Debt/CF from Ops. ⓘ	-10.9	3.1	-12.8	-0.2	6.9	-4.3	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	68.9%	46%	51.9%
Adj EPS ⓘ	NA	NA	31.9%	84.6%
BVPSⓘ	NA	NA	112.3%	24.8%
Share Price	-	-	17.7%	-8.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	27.1	-33.6	180.3	23.3	14.1	21.6	16.5
Op. Profit Mgn % ⓘ	-5.5	13	12.4	19.8	19.9	26.1	25.1
Net Profit Mgn % ⓘ	-16.5	6.1	17.8	18.5	15.5	18.9	19.3
Debt to Equity ⓘ	-2.2	-9.6	0.5	0.1	0.1	0.2	-
Working Cap Days ⓘ	0	223	164	267	355	326	78
Cash Conv. Cycle ⓘ	0	30	33	95	118	102	46

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	10.9	9.8
TTM Sales (₹ Cr.)	67.8	87
BVPS (₹) ⓘ	75.2	72.1
Reserves (₹ Cr.) ⓘ	78	77
P/BV ⓘ	3.32	3.46
PE ⓘ	22.83	25.36

From the Market
52 Week Low / High (₹)	229.95 / 328.00
All Time Low / High (₹)	102.75 / 339.00
Market Cap (₹ Cr.)	298
Equity (₹ Cr.)	11.9
Face Value (₹)	10
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

1.76

0.00

3.46

3.43

6.77

* Pledged shares as % of Promoter's holding (%)

Valuation of Trident Lifeline - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	5	10	22	32	45	68
Operating Expenses ⓘ +	5	8	19	25	36	50
Manufacturing Costs	0	1	5	5	6	13
Material Costs	3	6	11	16	25	28
Employee Cost	1	1	1	1	2	3
Other Costs ⓘ	1	1	3	3	3	7
Operating Profit ⓘ	-0	1	3	6	9	18
Operating Profit Margin (%)	-5.5%	13.0%	12.4%	19.8%	19.9%	26.1%
Other Income ⓘ +	0	0	1	1	2	3
Exceptional Items ⓘ	0	0	0	0	0	0
Interest ⓘ	1	0	0	0	1	1
Depreciation ⓘ	0	0	0	0	1	2
Profit Before Tax ⓘ	-1	1	3	7	10	18
Tax ⓘ	-0	0	-1	1	3	5
Profit After Tax	-1	1	4	6	7	13
PAT Margin (%)	-16.1%	6.6%	18.1%	19.0%	15.8%	19.3%
Adjusted EPS (₹)	-2.6	1.3	4.9	5.2	6.1	11.4
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	-3	-0	5	46	53	66
Share Capital ⓘ	3	5	8	11	11	11
Reserves ⓘ	-6	-5	-3	34	41	54
Debt +	6	5	2	3	6	14
Long Term Debt	6	5	1	0	4	6
Short Term Debt	0	0	1	3	2	8
Minority Interest	0	0	0	0	0	0
Trade Payables	2	4	5	5	8	10
Others Liabilities ⓘ	-1	2	1	3	8	10
Total Liabilities ⓘ	4	10	13	56	74	99
Fixed Assets
Net Fixed Assets ⓘ +	1	1	1	3	8	15
Gross Block	1	2	2	4	10	18
Accumulated Depreciation	0	1	1	1	2	3
CWIP ⓘ	0	0	0	0	4	1
Investments ⓘ	0	0	0	4	4	12
Inventories	1	5	4	7	11	17
Trade Receivables	1	1	5	12	14	20
Cash Equivalents	0	0	0	14	6	2
Others Assets ⓘ	1	2	3	16	27	33
Total Assets ⓘ	4	10	13	56	74	99

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-1	1	-0	-17	1	-3
PBT ⓘ	-1	1	3	7	10	18
Adjustment ⓘ	1	1	0	0	-1	1
Changes in Working Capital ⓘ	-0	0	-4	-23	-6	-18
Tax Paid ⓘ	0	0	0	-1	-2	-4
Cash Flow From Investing Activity ⓘ +	-0	-1	-0	-6	-11	-8
Capex	-0	-1	-0	-2	-9	-5
Net Investments	0	0	-0	-4	-0	-8
Others ⓘ	0	0	0	1	-2	5
Cash Flow From Financing Activity ⓘ +	1	-1	1	36	2	7
Net Proceeds from Shares ⓘ	1	2	3	35	0	0
Net Proceeds from Borrowing ⓘ	0	-2	-3	-1	3	3
Interest Paid ⓘ	-1	-0	-0	-0	-0	-1
Dividend Paid ⓘ	0	0	0	0	0	0
Others ⓘ	0	-1	1	2	-0	5
Net Cash Flow ⓘ	0	-0	0	14	-8	-4

Finance Ratio

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	N/A	N/A	183.4	23.87	14.34	22.05
ROCE (%)	N/A	N/A	55.11	25.1	19.11	27.66
Asset Turnover Ratio	1.14	1.38	1.94	0.92	0.69	0.78
PAT to CFO Conversion(x)	N/A	1	-0	-2.83	0.14	-0.23
Working Capital Days
Receivable Days	97	37	47	99	106	92
Inventory Days	69	118	75	63	75	74
Payable Days	202	194	157	112	90	114

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Trident Lifeline Ltd FAQs

The current trading price of Trident Lifeline on 17-Apr-2026 16:59 is ₹249.7.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Trident Lifeline stood at ₹297.9 Cr

The latest P/E ratio of Trident Lifeline as of 16-Apr-2026 is 22.83.

The latest P/B ratio of Trident Lifeline as of 16-Apr-2026 is 3.32.

The 52-week high of Trident Lifeline is ₹328.0 and the 52-week low is ₹229.9.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Trident Lifeline is ₹67.80 ( Cr.) .

About Trident Lifeline Ltd

The Company was originally incorporated as “Trident Lifeline Private Limited” as a Private Limited Company under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated January 09, 2014, issued by the Registrar of Companies, Gujarat, Dadra and Nagar Havelli. Subsequently, the Company was converted into a Public Limited Company pursuant to shareholders resolution passed at Extra-ordinary General Meeting of the Company held on June 02, 2022 and the name of the Company was changed to “Trident Lifeline Limited”. A fresh Certificate of Incorporation consequent upon Conversion from Private Limited Company to Public Limited Company dated June 10, 2022 was issued by the Registrar of Companies, Ahmedabad.

Trident Lifeline is engaged in the pharmaceutical business ethical marketing in domestic as well as international market. It is also engaged in distribution of pharmaceutical products through third party distribution network. It offers wide range of pharmaceutical formulations and products manufactured on contract manufacturing under loan lisence. It operates in India as well as African, Latin American and East Indian Countries. It has its presence through registered products or products under registration in countries like Bolivia, Cambodia, Cameroon, Chile, Ghana, Kenya, Myanamar, Nigeria, Peru, Sudan, Tajikistan, Uzbekistan, Venuzela.

The company is engaged in the business of marketing pharmaceutical products. For which it has obtain necessary approvals from FDA for getting the formulations manufacture from contract manufacturers on Loan License or on principle-to-principle basis. It also takes the necessary Trademark approvals & registrations wherever required. Its Pharma business operations are supported by various contract manufacturers having facilities which are approved by FDA/WHO and other relevant authorities. It typically works on contract manufacturing basis or at times purchase order basis, depending upon customer’s requirement, with manufacturer of pharma products. Presently the company operates with one contract manufacturer. The company has maintained relationship with the regular supplier, having FDA and WHO approved plant to supply pharma formulations. These units manufacture tablets, capsules, dry powder, syrup under its own brands.

Business area of the company

The company is engaged in the manufacturing and marketing of quality finished dosages. It is one of the fastest growing pharmaceutical companies in the SME segment providing unprecedented quality of healthcare products. It deals in Capsules, Tablets, Liquid Ointment, Gel, Ice Gel, Mouthwash, Paste, Solution, Suspension, Drypowders and Toothpaste. Its product portfolio comprises of vide range of drugs like Anti Bacterial, Anti Diarrheal, Anti Fungal, Anti Malerial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozol, Anti Histamine, Anti Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral Nyteraceutical and Non-steriodal anti-inflamatory drug (NSAIDS).

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Trident Lifeline Ltd (543616) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Trident Lifeline Share Price